Published in J Pharm Sci on December 01, 1983
Moisture sorption characteristics of freeze dried whey-grape beverage mix. J Food Sci Technol (2012) 0.88
Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts. AAPS PharmSciTech (2010) 0.82
Interaction of environmental moisture with powdered green tea formulations: relationship between catechin stability and moisture-induced phase transformations. J Agric Food Chem (2009) 0.77
Water-solid interactions in amorphous maltodextrin-crystalline sucrose binary mixtures. Pharm Dev Technol (2013) 0.75
Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci (1997) 2.86
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (1998) 2.08
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res (1994) 1.67
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res (1997) 1.57
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res (1995) 1.39
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 1.23
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci (1994) 1.23
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pharm Res (1998) 1.19
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm Res (1999) 1.13
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
The use of solution theories for predicting water vapor absorption by amorphous pharmaceutical solids: a test of the Flory-Huggins and Vrentas models. Pharm Res (1993) 1.08
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
Non-isothermal and isothermal crystallization of sucrose from the amorphous state. Pharm Res (1994) 1.02
Biology of membrane transport proteins. Pharm Res (1995) 1.02
Solid-state characteristics of amorphous sodium indomethacin relative to its free acid. Pharm Res (1999) 1.00
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci (1998) 0.99
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci (1997) 0.96
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
How does residual water affect the solid-state degradation of drugs in the amorphous state? J Pharm Sci (1996) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Kinetic analysis of the hydrolysis of lecithin monolayers by phospholipase A. Chem Phys Lipids (1971) 0.95
Wettability of pharmaceutical solids: estimates of solid surface polarity. J Pharm Sci (1976) 0.95
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res (1990) 0.94
Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res (1992) 0.94
Properties of citric acid at the glass transition. J Pharm Sci (1997) 0.93
Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res (1992) 0.93
Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci (1995) 0.93
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci (1987) 0.93
Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res (1988) 0.93
Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm (1998) 0.93
Analysis of models for determining intestinal wall permeabilities. J Pharm Sci (1980) 0.92
Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J Pharm Sci (1989) 0.92
Scaleup of oral extended-release dosage forms. Pharm Res (1993) 0.92
Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci (1988) 0.92
Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci (1989) 0.92
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci (1986) 0.92
A study of amorphous molecular dispersions of indomethacin and its sodium salt. J Pharm Sci (2001) 0.91
Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharm Res (1991) 0.91
Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci (1982) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci (1994) 0.90
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci (1999) 0.90
The relationship between "BET" and "free volume"-derived parameters for water vapor absorption into amorphous solids. J Pharm Sci (2000) 0.90
Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res (1997) 0.90
Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res (1998) 0.89
Mixture experimental design in the development of a mucoadhesive gel formulation. Pharm Res (1991) 0.89
Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm Dev Technol (1998) 0.89
Pharmacokinetics of alcohol following single low doses to fasted and nonfasted subjects. J Clin Pharmacol (1977) 0.89
The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res (1998) 0.88
Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J Theor Biol (1988) 0.88
Drug transport and targeting. Intestinal transport. Pharm Biotechnol (1999) 0.88
A theoretical model for the use of functional antagonism to estimate dissociation constants for agonists. J Pharmacol Methods (1982) 0.88
Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. J Pharm Sci (1996) 0.87
Hydration and dehydration of crystalline and amorphous forms of raffinose. J Pharm Sci (1995) 0.87
The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology (1990) 0.87
Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci (2000) 0.86
Uptake of L-carnitine by rat jejunal brush border microvillous membrane vesicles. Evidence of passive diffusion. Dig Dis Sci (1990) 0.86
Viscoelastic properties of poly(ethylene oxide) solution. J Pharm Sci (1994) 0.86
Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential. Gene Ther (2003) 0.85
Adhesion of hydroxypropyl cellulose films to low energy solid substrates. J Pharm Sci (1986) 0.85
Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery. Pharm Dev Technol (1998) 0.85
The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm Res (1999) 0.84
Solubility of nonelectrolytes in polar solvents III: Alkyl p-aminobenzoates in polar and mixed solvents. J Pharm Sci (1975) 0.84
The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur J Pharm Sci (2002) 0.84
Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells. AAPS PharmSci (1999) 0.84
Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm Res (1989) 0.84